Enterprise Value
7.997B
Cash
399.4M
Avg Qtr Burn
-116.8M
Short % of Float
6.41%
Insider Ownership
0.76%
Institutional Own.
-
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SKYTROFA (TransCon hGH) (lonapegsomatropin) Details Pediatric growth hormone deficiency | Approved Quarterly sales | |
YORVIPATH® (palopegteriparatide, developed as TransCon PTH) Details Adult hypoparathyroidism Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
TransCon hGH Details Adult growth hormone deficiency | BLA Submission | |
TransCon CNP Details Achondroplasia | Phase 2 Data readout | |
TransCon IL-2 B/y + TLR7/8 Details Solid tumor/s, Cancer | Phase 2 Data readout | |
TransCon IL-2 B/y Details Solid tumor/s, Cancer | Phase 2 Data readout | |
TransCon CNP Details Achondroplasia | Phase 2 Data readout | |
TransCon hGH/TransCon CNP combination Details Achondroplasia | Phase 2 Data readout | |
TransCon hGH Details Turner syndrome | Phase 2 Data readout | |
TransCon TLR7/8 Agonist +/- pembrolizumab Details Cancer, Solid tumor/s | Phase 2 Data readout |